Table 2 Open in new tab Multivariable...

Characteristic	3 mo	6 mo	12 mo
Skeletal muscle loss: >5% vs. ≤5%	2.667 (1.593–4.466)	.0002	1.707 (0.939–3.103)	.0797	2.103 (1.068–4.139)	.0314
Weight loss: >5% vs. ≤5%	0.851 (0.435–1.666)	.6380	1.835 (0.839–4.015)	.1287	2.096 (0.838–5.244)	.1136
Mutation		.0004		.0002
BRAF vs. WT	3.918 (1.837–8.355)		4.013 (1.914–8.415)		4.834 (2.030–11.515)	.0004
RAS vs. WT	1.489 (0.857–2.587)	.1580	1.618 (0.893–2.932)	.1123	1.467 (0.7435–2.894)	.2692
TAT loss: >5% vs. ≤5%	1.517 (0.836–2.753)	.1705	0.660 (0.326–1.334)	.2471	0.735 (0.297–1.818)	.5051
Age: ≥70 yr vs. <70 yr	1.156 (0.650–2.056)	.6208	1.325 (0.746–2.354)	.3374	2.436 (1.230–4.825)	.0106
Sex: Female vs. male	1.007 (0.607–1.673)	.9770	1.198 (0.679–2.112)	.5335	0.785 (0.409–1.508)	.4680

Characteristic	3 mo	6 mo	12 mo
Skeletal muscle loss: >5% vs. ≤5%	2.667 (1.593–4.466)	.0002	1.707 (0.939–3.103)	.0797	2.103 (1.068–4.139)	.0314
Weight loss: >5% vs. ≤5%	0.851 (0.435–1.666)	.6380	1.835 (0.839–4.015)	.1287	2.096 (0.838–5.244)	.1136
Mutation		.0004		.0002
BRAF vs. WT	3.918 (1.837–8.355)		4.013 (1.914–8.415)		4.834 (2.030–11.515)	.0004
RAS vs. WT	1.489 (0.857–2.587)	.1580	1.618 (0.893–2.932)	.1123	1.467 (0.7435–2.894)	.2692
TAT loss: >5% vs. ≤5%	1.517 (0.836–2.753)	.1705	0.660 (0.326–1.334)	.2471	0.735 (0.297–1.818)	.5051
Age: ≥70 yr vs. <70 yr	1.156 (0.650–2.056)	.6208	1.325 (0.746–2.354)	.3374	2.436 (1.230–4.825)	.0106
Sex: Female vs. male	1.007 (0.607–1.673)	.9770	1.198 (0.679–2.112)	.5335	0.785 (0.409–1.508)	.4680

Table 2

Multivariable Cox proportional hazard models showing associations between loss of skeletal muscle, weight and total adipose tissue at 3, 6, and 12 months following metastatic diagnosis with overall survival

Characteristic	3 mo		6 mo		12 mo
Characteristic	Hazard Ratio (95% CI)	p value	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value
Skeletal muscle loss: >5% vs. ≤5%	2.667 (1.593–4.466)	.0002	1.707 (0.939–3.103)	.0797	2.103 (1.068–4.139)	.0314
Weight loss: >5% vs. ≤5%	0.851 (0.435–1.666)	.6380	1.835 (0.839–4.015)	.1287	2.096 (0.838–5.244)	.1136
Mutation		.0004		.0002
BRAF vs. WT	3.918 (1.837–8.355)		4.013 (1.914–8.415)		4.834 (2.030–11.515)	.0004
RAS vs. WT	1.489 (0.857–2.587)	.1580	1.618 (0.893–2.932)	.1123	1.467 (0.7435–2.894)	.2692
TAT loss: >5% vs. ≤5%	1.517 (0.836–2.753)	.1705	0.660 (0.326–1.334)	.2471	0.735 (0.297–1.818)	.5051
Age: ≥70 yr vs. <70 yr	1.156 (0.650–2.056)	.6208	1.325 (0.746–2.354)	.3374	2.436 (1.230–4.825)	.0106
Sex: Female vs. male	1.007 (0.607–1.673)	.9770	1.198 (0.679–2.112)	.5335	0.785 (0.409–1.508)	.4680

Characteristic	3 mo		6 mo		12 mo
Characteristic	Hazard Ratio (95% CI)	p value	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value
Skeletal muscle loss: >5% vs. ≤5%	2.667 (1.593–4.466)	.0002	1.707 (0.939–3.103)	.0797	2.103 (1.068–4.139)	.0314
Weight loss: >5% vs. ≤5%	0.851 (0.435–1.666)	.6380	1.835 (0.839–4.015)	.1287	2.096 (0.838–5.244)	.1136
Mutation		.0004		.0002
BRAF vs. WT	3.918 (1.837–8.355)		4.013 (1.914–8.415)		4.834 (2.030–11.515)	.0004
RAS vs. WT	1.489 (0.857–2.587)	.1580	1.618 (0.893–2.932)	.1123	1.467 (0.7435–2.894)	.2692
TAT loss: >5% vs. ≤5%	1.517 (0.836–2.753)	.1705	0.660 (0.326–1.334)	.2471	0.735 (0.297–1.818)	.5051
Age: ≥70 yr vs. <70 yr	1.156 (0.650–2.056)	.6208	1.325 (0.746–2.354)	.3374	2.436 (1.230–4.825)	.0106
Sex: Female vs. male	1.007 (0.607–1.673)	.9770	1.198 (0.679–2.112)	.5335	0.785 (0.409–1.508)	.4680

For each follow-up time point, a single model was fit using the CT scans performed at the given time point.

Abbreviations: CI, confidence interval; CT, computed tomography; TAT, total adipose tissue; WT, wild type.

This Feature Is Available To Subscribers Only